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Glucose clamp studies are used to determine pharmacokinetics (PK) and pharmacodynamics (PD) of analogue insulins. With the 
development of longer-acting basal analogue insulins, including glargine 300 (Gla-300) and insulin degludec (IDeg), results from 
numerous glucose clamp studies are readily available. However, interpreting PK/PD profiles in a scientifically sound manner can 
be a challenging feat. This is the first in a series of publications that will suggest practical tips for interpreting and comparing 
results from glucose clamp studies. Variations in the glucose clamp methodology, duration of clamp studies and glucose clamp 
targets influence the study design and results significantly. Selection of study populations, including healthy patients or patients 
with Type 1 or 2 diabetes mellitus, has important implications. The dose of study insulin should reflect that of the general 
treatment population, and ideally steady-state conditions should be used. During the study the plasma insulin concentration 
and glucose infusion rate describe the pharmacokinetics and pharmacodynamics of the study insulin. With these practical tips 
in mind, results of glucose clamp studies can be interpreted in a scientifically correct manner. The next article in this series will 
discuss the interpretation of PK/PD profiles using two newly developed longer-acting basal analogue insulins: Gla-300 and IDeg.
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Introduction
According to the guidelines for the treatment of diabetes 
published by the Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA), treatment with exogenous 
insulins is recommended for patients diagnosed with Type 2 
diabetes mellitus who are unable to reach glycaemic control on 
oral antidiabetic agents.1 Insulin forms the cornerstone in the 
treatment of patients with Type 1 diabetes mellitus due to an 
absolute deficiency of insulin.2 The goal of treatment with 
exogenous insulins is to mimic physiological insulin secretion in 
patients with deficient endogenous insulin production to ensure 
maintenance of fasting blood glucose levels at 4–7 mmol/l.1
Although the insulin options available to the South African 
prescriber include analogue, human and premixed insulins, this 
article will focus on basal analogue insulins. Several basal 
analogue insulins are currently under development aiming at 
prolonged duration of action and more predictable absorption 
than the analogue insulins currently available.2–4
Regulatory approval of new biological products, including 
analogue insulins, requires complete description of 
pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the 
new chemical entities in humans.5 The glucose clamp study is 
regarded as the gold standard to establish PK and PD profiles of 
basal analogue insulins.6
A vast collection of data describing the time–action profiles of 
analogue insulins has been published recently.7–10 However, 
while the correct interpretation of these profiles can guide the 
prescriber in selecting the most appropriate treatment for a 
patient, this proves to be a challenging feat. This series of 
publications will discuss practical tips for the accurate 
interpretation of pharmacokinetic and pharmacodynamic 
profiles of analogue insulins obtained from glucose clamp 
studies.
Pharmacokinetics and pharmacodynamics of 
analogue insulins
Pharmacokinetics describes the relationship between dose 
administered and observed plasma concentration, whereas the 
relationship between plasma concentration and the response 
elicited is described by the pharmacodynamics.11 As such, 
pharmacokinetics is influenced by variables including dose, 
frequency of administration and route of administration. 
Pharmacodynamics may be affected by host factors such as 
receptor expression and sensitivity.11
The unique mode of protraction of longer-acting analogue 
insulins, including insulin glargine (Gla-300) and degludec 
(IDeg), results in extended duration of action. Gla-300 is soluble 
at acidic pH, and after injection into the subcutaneous tissue 
microprecipitates form a more compact soluble depot with 
smaller surface area in comparison with Gla-100, from which 
active monomers are steadily released.12 In contrast, IDeg form 
multi-hexamers after administration in the subcutaneous tissue 
resulting in the formation of a soluble depot from which active 
monomers are steadily released.13 The long half-life of these 
insulins translates into extended duration of action and therefore 
allows once-daily administration.2 Half-life refers to the time 
required for the original plasma concentration of an administered 
drug to be reduced by half, which is determined by the rate at 
which drug is eliminated from the central compartment (plasma). 
For drugs with an intravenous bolus dose administration the 
original plasma concentration is established very rapidly so the 
plasma concentration profile over time is mainly determined by 
the bolus dose and factors that influence the rate at which 
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regarded as the gold standard to establish PK and PD profiles of 
basal analogue insulins.6
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profiles of analogue insulins obtained from glucose clamp 
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relationship between plasma concentration and the response 
elicited is described by the pharmacodynamics.11 As such, 
pharmacokinetics is influenced by variables including dose, 
frequency of administration and route of administration. 
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The unique mode of protraction of longer-acting analogue 
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multi-hexamers after administration in the subcutaneous tissue 
resulting in the formation of a soluble depot from which active 
monomers are steadily released.13 The long half-life of these 
insulins translates into extended duration of action and therefore 
allows once-daily administration.2 Half-life refers to the time 
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plasma concentration decreases, including the rate of 
metabolism and the rate of excretion.
In the case of basal analogue insulins, this scenario is complicated 
by the slow release of insulin into the central compartment. 
Typically, this would lead to a ‘flattened’ concentration–time 
profile, e.g. if the rate of insulin entering the plasma compartment 
equals the rate at which insulin is eliminated from the same 
compartment, the concentration–time profile will be a horizontal 
line because the plasma insulin concentration does not change 
over time. This flattened profile enables less frequent dosing 
with the intermediate and long-acting basal analogue insulins. 
Factors that establish insulin plasma concentration include the 
dose, rate of release of insulin monomers and rate of absorption 
from the site of administration, in this case subcutaneous depots. 
Factors that influence the rate at which plasma insulin 
concentration decreases include the rate of metabolism and the 
rate of excretion.6 Many of these factors are related to the 
physicochemical properties of the exogenous insulin, which can 
be manipulated to modify the pharmacokinetics of the drug. 
Since the plasma concentration directly relates to response, 
these modifications also have an impact on the clinical outcome 
observed with different analogue insulins.
Glucose clamp study procedure
Originally established to describe insulin secretion and resistance 
during the 1970s,14 the glucose clamp methodology has been 
adapted to provide PK/PD profiles for long-acting basal analogue 
insulins. In brief, glucose clamp studies assess the intravenous 
glucose infusion rate required to maintain blood glucose levels 
at a predetermined target level, the clamp target, after 
administration of a long-acting basal analogue insulin.6
Variations of the glucose clamp study have been developed 
based on the glucose clamp target, i.e. the euglycemic and 
hyperglycaemic models. With the euglycemic clamp model a 
hyperinsulinaemic state is created through the infusion of insulin 
to reach a plasma insulin concentration of approximately 100 
μU/ml. At the same time glucose is infused to reach the 
predefined plasma glucose concentration, which can either be 
the physiological plasma levels (euglycemic clamp model) or an 
elevated level (hyperglycaemic clamp model).14,15 As the 
euglycemic clamp model is most commonly employed to 
determine the time–action profile of long-acting analogue 
insulins, this model will be the focus of the article. The euglycemic 
glucose clamp methodology is illustrated in Figure 1.
After an overnight fast, a 20% dextrose solution and/or rapid-
acting insulin is administered intravenously to reach clamp 
glucose and insulin target. Insulin is administered to suppress 
endogenous insulin and hepatic glucose production. Potassium 
phosphate may also be administered to prevent hypokalaemia.15 
Once the clamp target has been reached, infusion of rapid-acting 
insulin is gradually tapered off and discontinued prior to 
administration of the long-acting study insulin. The long-acting 
study insulin is administered at a predetermined dose. Blood 
samples are collected at regular intervals to determine blood 
glucose and plasma insulin concentrations. Based on the blood 
glucose levels determined, the glucose infusion rate is adjusted 
to maintain clamp target.7,8
Interpretation of glucose clamp results
Data obtained from glucose clamp studies are used to describe 
the duration of action of the study insulin and inter-individual 
variability observed among the study population. General 
outcome measures of glucose clamp studies are described, 
along with potential influencing factors, in Table 1.
The data obtained from glucose clamp studies are commonly 
represented in terms of the plasma insulin concentration 
(indicative of PK) and glucose infusion rate (indicative of PD) 
(Figure 2). The ideal long-acting analogue insulin will display a 
flat, peakless PD profile mimicking physiological endogenous 
insulin secretion.17 Within-subject variability, i.e. variation in the 
response produced within the same individual after doses with 
the same insulin, may be determined from repeat clamp studies 
performed on the same study population. Within-subject 
variability is a clinically relevant measure and the ideal longer-
acting insulin will have very low intra-individual variability. In 
clinical practice this translates into a predictable response after 
administration of the same dose of insulin on different days. This 
is particularly important to avoid unexpected hypoglycaemic 
episodes when the same dose is injected on different days.17
Several factors must be taken into consideration when 
interpreting the results of glucose clamp studies. A number of 
these factors are described below.
Figure 1. Euglycemic clamp methodology.
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 Clamp methodology
Glucose clamp studies can be performed manually or using an 
automated Biostator system MTB (Medizintechnik, Amstetten, 
Germany). During a manual clamp study glucose levels are 
monitored at intervals of several minutes, whereas the use of the 
Biostator allows for the monitoring of glucose levels every 
minute.15 A major advantage of the use of the Biostator is the 
exclusion of investigator bias in terms of adjustment of the 
glucose infusion rate.
 Duration of glucose clamp study
A standard duration of glucose clamp study has not been 
established. The duration of euglycemic clamp studies for Gla-
300 ranges from 24 h to 36 h8,18,19 while euglycemic clamp studies 
for IDeg ranges from 24 h to 42 h.7,20 It must be considered that 
the duration of a glucose clamp study may be shorter than the 
duration of action of the study insulin. Indeed, the duration of 
action of Gla-300 has been reported to be in excess of 30 h and 
the duration of action of IDeg as 42 h.4
The differing clamp duration of these studies may confound 
comparison of the results and determination of the duration of 
action of a longer-acting insulin analogue. The maximum 
duration of action of a longer-acting insulin analogue that can 
be determined with a glucose clamp study is equal to the 
duration of the clamp. Therefore, only where the duration of 
action of the insulin is shorter than the duration of the clamp can 
an accurate duration of action be reported.
 Study population
Results from glucose clamp studies performed in healthy 
volunteers,9,30 patients diagnosed with Type 1 diabetes 
mellitus7,8,21 and Type 2 diabetes mellitus22,23 have been published. 
However, for each population a number of potentially 
confounding factors must be considered when interpreting the 
results.
Where glucose clamp studies are performed in healthy volunteers 
or patients diagnosed with Type 2 diabetes mellitus, the effect of 
endogenous insulin secretion on the glucose infusion rate (GIR) 
must be accounted for. In order to compensate for secretion of 
endogenous insulin, the pre-study baseline insulin:C-peptide 
ratio is commonly used as reference24 as C-peptide is secreted in 
equimolar amounts to insulin. Monitoring of serum C-peptide 
levels may be used to indicate the secretion of endogenous 
insulin. A reduction in serum C-peptide levels is indicative of a 
decline in endogenous insulin secretion.15 Adjusting for 
endogenous insulin, using C-peptide concentrations, provides a 
more accurate assessment of the pharmacokinetics of an 
exogenous insulin and is particularly useful when assessing 
Table 1: General outcome measures of the euglycemic glucose clamp study
*End of action may occur prior to end of study and is defined as GIR = 0 mmol/kg/min.
Parameters Definition Influencing factors Clinical implication(s)
Area under the curve (AUC)16 Total quantity of drug the subject was 
exposed to
Dose Total amount of glucose utilised during 
clamp due to exogenous insulin
Frequency of administration
Elimination rate
Elimination half-life (t½)16 Time required for drug concentration to 
be reduced by half
Rate of metabolism Surrogate measurement of duration of 
action of the exogenous insulin
Rate of excretion




Glucose infusion rate (GIR)14 Rate at which i.v. glucose must be infused 
to maintain the clamp target
Glucose utilisation Glucose intake
Endogenous insulin production
Investigator bias
End of action3 Time when blood glucose concentration 
reaches 8.3 mmol/l*






Figure 2. PK/PD profile of a longer-acting basal analogue insulin where 
(A) indicates the ideal PK/PD profile and (B) indicates a non-ideal PK/
PD profile. The PK/PD profile of a longer-acting basal analogue insulin 
obtained from a euglycemic glucose clamp study should ideally have 
a flat, peakless serum insulin concentration curve suggesting reduced 
risk of hypoglycaemia.6 A minimum duration of action of 24 h should be 
observed in order to allow for once-daily administration.2 It should be 
considered that the full duration of action of the study insulin may not 
be observed during the period of the glucose clamp study.
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determine blood glucose levels and the GIR adapted accordingly 
to maintain blood glucose levels at the predetermined clamp 
target. GIR is therefore indicative of glucose utilisation and 
metabolism.15,29
 Plasma insulin concentration
During the clamp study plasma insulin concentration is 
determined using immunoassays with radio-labelled or enzyme-
linked antibodies. These antibodies recognise a peptide 
sequence in the insulin molecule, and this allows for the 
quantification of insulin concentrations based on a detectable 
signal generated.15 However, antibodies to specific analogue 
insulins are not readily available and therefore endogenous and 
exogenous insulins may not be differentiated. Furthermore, 
these assays do not accurately quantify C-peptide, a product of 
the conversion of endogenous proinsulin to insulin, which may 
be used to distinguish endogenous and exogenous insulins.15 In 
order to ensure that the insulin concentration reported is 
accurate, the lower limit of quantification (LLoQ) of these assays 
must be reported.24 Levels of insulin lower than the LLoQ cannot 
be accurately determined using the currently available assays.
It must be considered that insulin bound to albumin, a 
phenomenon known as protein binding,30 will not be accurately 
detected by antibody assays. Acetylated insulins have been 
demonstrated to bind to albumin, resulting in an extended 
duration of action,30 but may result in an underestimation of 
plasma insulin concentration. Indeed, accurately determining 
the plasma concentrations of acetylated IDeg basal analogue 
insulin is not currently possible with immunoassays.4
Glucose clamp studies, when used appropriately, provide 
valuable insight into the time–action profiles of longer-acting 
insulin analogues, such as Gla-300 and IDeg. These studies are 
useful to determine the duration of action of an insulin analogue 
translating into frequency of administration, as well as inter- and 
intra-individual variability, translating into predictable response 
after repeated administration. Conclusions regarding the safety 
and efficacy of longer-acting insulin analogues, however, cannot 
be drawn from the results of glucose clamp studies. In order to 
establish the application of new analogue insulins in the clinical 
setting, phase three clinical trials with specific outcomes for 
diabetes are required.
Conclusion
Even though glucose clamp studies are recommended for the 
determination of the time–action profiles of long-acting 
analogue insulins, the advantages and confounding factors of 
glucose clamp methodology must be considered when 
interpreting and comparing results from different glucose clamp 
studies. However, using the guide as set out above, glucose 
clamp studies can be interpreted in a scientifically correct 
manner. The next article in this series will discuss the 
interpretation of PK/PD profiles of two newly developed longer-
acting basal analogue insulins: Gla-300 and IDeg.
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biosimilarity between drugs as demonstrated by a recent study 
that evaluated the biosimilarity between different insulin 
glargine products.9 While this approach may reduce the reported 
effect of endogenous insulin on glucose concentration, it does 
not entirely eliminate this confounding metabolic effect of the 
endogenous insulin.
Clamp studies performed in a healthy study population are 
fraught with complications. It has been demonstrated that time–
action profiles for insulin glargine obtained in studies using 
healthy volunteers9 did not reflect that of a study population of 
patients with Type 1 diabetes mellitus.22,25 Furthermore, extended 
duration of action of insulin in healthy volunteers may be 
observed due to continuous endogenous insulin secretion.25
The use of a study population of patients diagnosed with Type 1 
diabetes mellitus is recommended, as endogenous insulin 
secretion will not affect results obtained.3,25 However, during the 
initial stages of Type 1 diabetes mellitus β-cell function may not 
be entirely lost, resulting in production of endogenous insulin.26 
During infusion of glucose and exogenous insulin to establish 
the hyperinsulinaemic euglycemic state prior to initiation of the 
clamp study, the duration of action of the exogenous insulin 
injected prior to the clamp and time of discontinuation prior to 
administration of study insulin must be considered to avoid 
masking the glucose-lowering effect of the study insulin.24
 Dose of study insulin
Glucose clamp studies aim to provide information as to the 
pharmacokinetic profile to be expected in the general treatment 
population and administration of study insulin should therefore 
reflect the doses and administration times of the general 
treatment population.27 Glucose clamp studies have been 
performed using a single dose of study insulin. However, this 
does not reflect the use of long-acting analogue insulins in the 
treatment population. The time–action profiles of long-acting 
analogue insulins are thus best studied once steady-state 
conditions have been reached.3 Steady-state is achieved when 
the absorption of a drug is equal to its elimination, after 
approximately four to five half-lives. It is recommended that 
glucose clamp studies for long-acting insulin analogues are 
performed at steady-state conditions in a study population of 
patients diagnosed with diabetes mellitus.3
It has been suggested that the results of clamp studies where the 
study insulin was administered during the morning cannot be 
directly compared with those of clamp studies where insulin was 
administered at night.28 As the majority of patients using basal 
analogue insulins administer these at night, the same dosing 
schedule should be followed in glucose clamp studies.27 
However, a direct comparison of the results of glucose clamp 
studies of Gla-100 using morning and evening administration 
did not reveal a marked difference between the dosing times.28
 Glucose infusion rate
Glucose clamp studies quantify the total volume of glucose 
required to maintain blood glucose levels at a predetermined 
clamp target after administration of a long-acting insulin 
analogue.7,8 The volume of glucose required during the clamp 
period to maintain clamp target is indicated as the glucose 
infusion rate (GIR).14 Samples are collected at regular intervals to 
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